Krempa David
Chief Business Officer
Krempa David has filed 5 SEC Form 4 filings (15 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Aug 24, 2026.
On the most recent filing, Krempa David is listed as Chief Business Officer at Eton Pharmaceuticals, Inc. Inside the rolling window, Krempa David reported no open-market purchases and 4 open-market sales totaling $4.9M in ETON. The largest disclosed transaction in the window is a sale of 25,000 ETON shares on Aug 24, 2026, worth $1.6M.
Companies traded
Other insiders at ETON
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.9M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Krempa David made?
Krempa David has filed 5 SEC Form 4 filings (15 transaction rows) across 1 company since 2025.
Which companies does Krempa David trade?
Krempa David has filed SEC Form 4 disclosures for 1 company, including ETON.
When was Krempa David's most recent SEC Form 4 filing?
Krempa David's most recent SEC Form 4 filing on Tracefour is dated Aug 24, 2026.
What is Krempa David's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Krempa David is listed as Chief Business Officer.
What is Krempa David's total buy and sell value in the current window?
Inside the rolling retention window, Krempa David bought $0 and sold $4.9M based on SEC Form 4 filings.
What was Krempa David's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 25,000 ETON shares on 2026-08-24, worth $1.6M, per SEC Form 4 filings.